The 1st ISCC
November 19, 1996
KKR Hotel Tokyo (Takehashi Kaikan)
Program
I Apoptosis as a New Target in Cancer Chemotherapy
Chairperson: Yoshiyuki Hashimoto (Sasaki Institute)
Mikihiko Naito (Univ. Tokyo)
Scott Kaufmann (Mayo Clinic)
II New Drugs:Basic and Clinical Aspects
Chairpersons: David R. Parkinson (NCI)
Yutaka Ariyoshi (Aichi Hospital)
1. UCN-01
Ken Yamaguchi (National Cancer Center Research Inst.)
Shiro Akinaga (Kyowa Hakko Kogyo Co., Ltd.)
Edward A. Sausville (NCI)
Yasuhiro Shimada (National Cancer Center Hospital)
2. UFT and S-1
Tetsuhiko Shirasaka (Taiho Pharmaceutical Co. Ltd.)
Noboru Horikoshi (Cancer Chemotherapy Center)
Richard Pazdur (Univ. Texas)
Chairpersons: Edward A. Sausville (NCI)
Makoto Ogawa (Aichi Cancer Center)
3. Taxol and Taxotere
David R. Parkinson (NCI)
Nagahiro Saijyo (National Cancer Center Research Inst.)
Yasutsuna Sasaki (National Cancer Center Hospital East)
4. CPT-11
Henry C. Pitot (Mayo Clinic)
Seigo Sawada (Yakult Co., Ltd.)
Masahiro Fukuoka (Kinki Univ,)
III Preclinical Drugs of Interst:Basic and Some Clinical Informations
Chairpersons: Bruce A. Chabner (MGH Cancer Center)
Takashi Tsuruo (Univ. Tokyo)
1. Spicamycin
Junichiro Mochizuki (Kirin Brewery Co., Ltd.)
2. KW2149
Koji Mikami (Fukuoka Univ.)
3. CNDAC
Akira Matsuda (Hokkaido Univ.)
4. TAS-103
Teruhiro Utsugi (Taiho Pharmaceutical Co., Ltd.)
Ross C. Donohower (Johns Hopkins Univ.)
5. dFCTP-11
Akiko Tohgo (Daiichi Pharmaceutical Co., Ltd.)
6. MDR gene therapy
Yoshikazu Sugimoto (Cancer Chemotherapy Center)
IV Future Perspectives on Molecular Target Therapy
Chairperson:Haruo Sugano (Cancer Chemotherapy Center)
Bruce A. Chabner (MGH Cancer Center)
